Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

NCT00761787
View directory record Official record
Conditions
Graft Rejection, Heart Disease
Interventions
Not listed
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

NCT05837455
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated Not applicable Interventional

The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors

NCT01224509
View directory record Official record
Conditions
Cervical Prostaglandin EP3 Receptors, Pregnancy
Interventions
Mifepristone, Non-treatment
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2010 · Synced Oct 20, 2026, 2:53 AM EDT
Not yet recruiting Not applicable Interventional

Smoking Cessation Intervention for Young Adults Using MTM: A Randomized Controlled Trial

NCT07104006
View directory record Official record
Conditions
Tobacco Use Disorder/Cigarette Smoking
Interventions
Multi-Theory Model (MTM)-Based Smoking Cessation Program
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 29 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Not applicable Interventional

Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain

NCT06044649
View directory record Official record
Conditions
Chronic Pain, Neck Pain, Back Pain
Interventions
Cognitive Behavioral Therapy, Acceptance and Commitment Therapy, Emotional Awareness and Expression Therapy, Treatment as Usual
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational

Molecular Phenotyping of Asthma in Sickle Cell Disease

NCT01879592
View directory record Official record
Conditions
Sickle Cell Disease, Asthma
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 20 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated No phase listed Observational

Identify microRNAs in Cachexia in Pancreatic Carcinoma

NCT05275075
View directory record Official record
Conditions
Resectable Pancreatic Adenocarcinoma
Interventions
Pancreatic cancer microRNA and messenger RNA expression.
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

NCT00899028
View directory record Official record
Conditions
Lung Cancer
Interventions
comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis, microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review, diagnostic bronchoscopy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 20, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Infrared and Broadband Light for Skin Aging

NCT03243981
View directory record Official record
Conditions
Aging
Interventions
Sciton SkinTyte (800-1800 nm) with Broadband Light Technology
Device
Lead sponsor
Stanford University
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200
View directory record Official record
Conditions
Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
ADCT-502
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 20, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NCT01396239
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AVI-4658 (Eteplirsen), Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 20, 2026, 2:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects

NCT00762801
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 20, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Longitudinal Follow-up of Brief Parenting Interventions to Reduce Risk of Child Physical Maltreatment

NCT04059185
View directory record Official record
Conditions
Parenting, Child Behavior, Child Rearing
Interventions
Triple P-Level 2, Play Nicely, Usual care
Other
Lead sponsor
Tulane University
Other
Eligibility
2 Years and older
Enrollment
1,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
View directory record Official record
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders

NCT01274026
View directory record Official record
Conditions
Phenylketonuria, Behavior and Behavior Mechanisms, PAH Gene Expression
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
2 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 20, 2026, 2:53 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT06559176
View directory record Official record
Conditions
Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Interventions
PM359
Biological
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

NCT00897247
View directory record Official record
Conditions
Malignant Mesothelioma, Pulmonary Complications
Interventions
microarray analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 20, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

NCT00536874
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational

A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease

NCT01194362
View directory record Official record
Conditions
Aortic Valve Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions
Datopotamab Deruxtecan
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Completed No phase listed Observational

Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

NCT01118078
View directory record Official record
Conditions
Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Rhabdoid Tumor of the Kidney, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor, Stage V Wilms Tumor
Interventions
DNA methylation analysis, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 20, 2026, 2:53 AM EDT
Terminated Phase 2 Interventional Results available

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

NCT01709474
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Vitamin D3 6000 IU, Vitamin D3 400 IU
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 20, 2026, 2:53 AM EDT